Luseogliflozin (Lusefi) use in adults with type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, non-interventional observational project enrolling adults with type 2 diabetes who were started on Lusefi 2.5 mg once daily in routine practice. Patients who have an insufficient response may have their dose increased to 5 mg once daily at the treating physician's discretion. Key measures include HbA1c, estimated glomerular filtration rate (eGFR), blood pressure, body weight, and other metabolic and hemodynamic parameters collected over approximately six months. All data are collected during routine clinic visits to describe real-world effectiveness and tolerability.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women aged 18 years and older.
* Patients with type 2 diabetes.
* Written informed consent of the patient to participate in the study.
* No conditions that require emergency medical aid.
* Treatment with luseogliflozin started 7 to 30 days prior to the inclusion visit as part of routine clinical practice and in accordance with the SmPC approved in the Russian Federation.
* Presence of data on the parameters of interest (HbA1c, eGFR, BP, body weight), dated no later than 15 days from the date the treatment with luseogliflozin was started

Exclusion Criteria:

* Patients cannot be included in this study if they meet at least one of the following exclusion criteria:
* Known hypersensitivity to luseogliflozin or other components of Lusefi®.
* Type 1 diabetes.
* Decompensated type 2 diabetes.
* Pregnancy, breastfeeding, or planned pregnancy during the study and at least two months after the study.
* Severe renal failure (eGFR \<30 mL/min/1.73 m2), end-stage chronic kidney disease (CKD) or dialysis, as the treatment is predicted to be ineffective in this population of patients.
* Diabetic ketoacidosis, diabetic coma or precoma.
* Severe infections, pre- and postoperative period, or severe injury.
* Any suspected or confirmed malignant neoplasm, including a history of malignancy within ≤5 years prior to screening, excluding successfully treated basal cell carcinoma and squamous cell carcinoma of the skin or in situ cervical cancer.
* Urinary tract infection (confirmed or suspected).
* Other concomitant disorders considered by the investigator to affect the natural progression of the disease and significantly impact the treatment results.
* Predictable unwillingness of the patient to adhere to the treatment regimen and/or cooperate with the investigator.
* Participation of the patient in another clinical study within 3 months (6 months for biological medicinal products) prior to the inclusion visit or during this study.

Where it's running

• GBUZ hospital
  Anapa, Russia Recruiting

Study contacts

• Principal investigator: Marina Shestakova — Endocrinology Research Centre
• Study coordinator: Ekaterina Erina
• Email: ekaterina.erina@servier.com
• Phone: +7 495 9370700

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Acupuncture plus vitamin B12 for diabetic heart nerve damage

  This study tests whether adding acupuncture to standard care and vitamin B12 can help adults with type 2 diabetes who have damaged the nerves that control the heart.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07907536

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Body composition changes after starting GLP-1 therapies in adults with obesity or type 2 diabetes

  This study will follow adults with obesity and/or type 2 diabetes who are starting or adjusting a GLP-1 receptor agonist to see how their muscle and fat change over about a year.

  Recruiting at 2 sites Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Mexico City, Mexico City and 1 other locations · NCT07835360

• Single-dose PK study of HRS-4729 in adults with and without kidney impairment

  This study tests a single dose of HRS-4729 to see how the body handles it in adults with various levels of kidney function compared with healthy adults.

  Recruiting Phase 1 Fujian Shengdi Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07807059

• Once-daily ASC30 to See if it helps adults with obesity or overweight and Type 2 diabetes

  This study tests three daily doses of ASC30 against placebo in adults who are overweight or obese and have Type 2 diabetes to see if it helps with weight loss and safety over time.

  Recruiting at 6 sites Phase 3 Ascletis Pharma Inc · Birmingham, Alabama and 134 other locations · NCT07743450

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.